Malignancies in transplanted patients: Multidisciplinary evaluation and switch to mTOR inhibitors after kidney transplantation – experiences from a prospective, clinical, observational study

References

• Adami J, Gabel H, Lindelof B, Ekstrom K, Rydh B, Glimelius B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 2003;89:1221–7.
   PubMed Web of Science ®Google Scholar
• Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant 2010;10:1889–96.
   PubMed Web of Science ®Google Scholar
• Engels EA, Pfeiffer RM, Fraumeni JF, Jr, Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011;306:1891–901.
   PubMed Web of Science ®Google Scholar
• Krynitz B, Edgren G, Lindelof B, Baecklund E, Brattstrom C, Wilczek H, et al. Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008-A Swedish population-based study. Int J Cancer 2013;132:1429–38.
   PubMed Web of Science ®Google Scholar
• Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer 2009;125:1747–54.
   PubMed Web of Science ®Google Scholar
• Ajithkumar TV, Parkinson CA, Butler A, Hatcher HM. Management of solid tumours in organ-transplant recipients. Lancet Oncol 2007;8:921–32.
   PubMed Web of Science ®Google Scholar
• Kauffman HM. Malignancies in organ transplant recipients. J Surg Oncol 2006;94:431–3.
   PubMed Web of Science ®Google Scholar
• Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007;370:59–67.
   PubMed Web of Science ®Google Scholar
• Miao Y, Everly JJ, Gross TG, Tevar AD, First MR, Alloway RR, et al. De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation 2009;87:1347–59.
   PubMed Web of Science ®Google Scholar
• Lott DG, Manz R, Koch C, Lorenz RR. Aggressive behavior of nonmelanotic skin cancers in solid organ transplant recipients. Transplantation 2010;90:683–7.
   PubMed Web of Science ®Google Scholar
• Webster AC, Craig JC, Simpson JM, Jones MP, Chapman JR. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant 2007;7:2140–51.
   PubMed Web of Science ®Google Scholar
• Kiberd BA, Keough-Ryan T, Clase CM. Screening for prostate, breast and colorectal cancer in renal transplant recipients. Am J Transplant 2003;3:619–25.
   PubMed Web of Science ®Google Scholar
• Alberu J, Pascoe MD, Campistol JM, Schena FP, Rial Mdel C, Polinsky M, et al. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation 2011;92:303–10.
   PubMed Web of Science ®Google Scholar
• Campbell SB, Walker R, Tai SS, Jiang Q, Russ GR. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 2012;12:1146–56.
   PubMed Web of Science ®Google Scholar
• Budde K, Sommerer C, Rath T, Reinke P, Haller H, Witzke O, et al. Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial. J Nephrol 2015;28:115–23.
   PubMed Web of Science ®Google Scholar
• Cao C, Subhawong T, Albert JM, Kim KW, Geng L, Sekhar KR, et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 2006;66:10040–7.
   PubMed Web of Science ®Google Scholar
• Albert JM, Kim KW, Cao C, Lu B. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther 2006;5:1183–9.
   PubMed Web of Science ®Google Scholar
• Taylor C, Munro AJ, Glynne-Jones R, Griffith C, Trevatt P, Richards M, et al. Multidisciplinary team working in cancer: what is the evidence? BMJ 2010;340:c951.
   PubMed Web of Science ®Google Scholar
• Stairmand J, Signal L, Sarfati D, Jackson C, Batten L, Holdaway M, et al. Consideration of comorbidity in treatment decision-making in multidisciplinary cancer team meetings: a systematic review. Ann Oncol 2015;26:1325–32.
   PubMed Web of Science ®Google Scholar
• Opelz G, Dohler B. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation 2009;87:795–802.
   PubMed Web of Science ®Google Scholar
• Kowalski RJ, Post DR, Mannon RB, Sebastian A, Wright HI, Sigle G, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006;82:663–8.
   PubMed Web of Science ®Google Scholar
• Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 2004;91:1420–4.
   PubMed Web of Science ®Google Scholar
• Lamb BW, Green JS, Benn J, Brown KF, Vincent CA, Sevdalis N. Improving decision making in multidisciplinary tumor boards: prospective longitudinal evaluation of a multicomponent intervention for 1,421 patients. J Am Coll Surg 2013;217:412–20.
   PubMed Web of Science ®Google Scholar
• Kidger J, Murdoch J, Donovan JL, Blazeby JM. Clinical decision-making in a multidisciplinary gynaecological cancer team: a qualitative study. BJOG 2009;116:511–17.
   PubMed Web of Science ®Google Scholar
• Aapro M, Andre F, Blackwell K, Calvo E, Jahanzeb M, Papazisis K, et al. Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. Ann Oncol 2014;25:763–73.
   PubMed Web of Science ®Google Scholar
• Opelz G, Dohler B, Ruhenstroth A, Cinca S, Unterrainer C, Stricker L, et al. The collaborative transplant study registry. Transplant Rev (Orlando) 2013;27:43–5.
   PubMedGoogle Scholar